Carbonic anhydrase inhibitors: Anticonvulsant sulfonamides incorporating valproyl and other lipophilic moieties

Journal of Medicinal Chemistry

Volumn 45, Issue 2, 2002, Pages 312-320

  Masereel, Bernard ^a   Rolin, Stéphanie ^a   Abbate, Francesco ^b   Scozzafava, Andrea ^b   Supuran, Claudiu T ^b  

^a UNIVERSITY OF NAMUR   (Belgium)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1,3,4 THIADIAZOLESULFONAMIDE DERIVATIVE; 5 ADAMANTYLCARBOXAMIDOSULFONAMIDE; 5 BENZOYLAMIDOSULFONAMIDE; 5 PIVALOYLAMIDO 1,3,4 THIADIAZOLE 2 SULFONAMIDE; 5 TOLUENESULFONYLAMIDOSULFONAMIDE; 5 VALPROYLAMIDO 1,3,4 THIADIAZOLE 2 SULFONAMIDE; ACETAZOLAMIDE; ADAMANTANE DERIVATIVE; ANTICONVULSIVE AGENT; CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE 1 INHIBITOR; CARBONATE DEHYDRATASE 2 INHIBITOR; CARBONATE DEHYDRATASE 4 INHIBITOR; CARBONATE DEHYDRATASE II; CARBONATE DEHYDRATASE INHIBITOR; SULFONAMIDE; THIADIAZOLE DERIVATIVE; TOLUENE DERIVATIVE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN CIRCULATION; CONTROLLED STUDY; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITOR INTERACTION; INHIBITION KINETICS; LIPOPHILICITY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; VASODILATATION;

ACETAZOLAMIDE; ANIMALS; ANTICONVULSANTS; CARBONIC ANHYDRASE I; CARBONIC ANHYDRASE II; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASE IV; ELECTROSHOCK; FRUCTOSE; HUMANS; MALE; MICE; MODELS, MOLECULAR; SEIZURES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 0037122779     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0109199     Document Type: Article

References (76)

1. Carbonic anhydrase inhibitors and their therapeutic potential
2. Carbonic anhydrase inhibitors
3. Carbonic anhydrase inhibitors
4. Carbonic anhydrase: Chemistry, physiology and inhibition
5. Communicating hydrocephalus secondary to diffuse meningeal spread of Wegener's granulomatosis: Case report and literature review
6. Acetazolamide in the treatment of seizures
7. A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia
8. A treatment for tardive dyskinesia and some other extrapyramidal symptoms
9. Effects of acetazolamide on myotonia
10. Familial hypokalemic periodic paralysis. Clinical, diagnostic and therapeutic aspects
11. Medical treatment of essential tremor and Parkinson's disease
12. Acetazolamide plus low-dose dexamethasone is better than acetazolamide alone to ameliorate symptoms of acute mountain sickness
13. Acetazolamide and high altitude disease
14. Topiramate: Preclinical evaluation of structurally novel anticonvulsant
15. Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy
16. A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat
17. Newer anticonvulsants: Comparative review of drug interactions and adverse effects
18. Pharmacokinetics and pharmacodynamics of topiramate
19. Progress report on new antiepileptic drugs: Summary of the Fifth Eilat Conference
20. Anticonvulsant activity of analogues of acetazolamide
21. Mechanism of action of valproate: A commentary
22. New formulations of drugs in epilepsy
23. Effects of valproate derivatives. I. Antiepileptic efficacy of amides, structural analogs and esters
24. Effects of valproate derivatives. II. Antiepileptic efficacy in relation to chemical structures of valproate sugar esters
25. Novel phosphonic and phosphonic acid analogues of the anticonvulsant valproic acid
26. GABA uptake inhibitors. Design, molecular pharmacology and therapeutic aspects
27. GABA uptake inhibitors: Relevance to antiepileptic drug research
28. GABAA receptor agonists, partial agonists, and antagonists. Design and therapeutic prospects
29. Piperidinyl-3-phosphinic acids as novel uptake inhibitors of the neurotransmitter gamma-aminobutyric acid (GABA)
30. Effects of GABAA receptors activation on brain glucose metabolism in normal subjects and temporal lobe epilepsy (TLE) patients. A positron emission tomography (PET) study. Part I: Brain glucose metabolism is increased after GABAA receptors activation
31. Anticonvulsant activity of the glial GABA uptake inhibitor, THAO, in chemical seizures
32. Carbonic anhydrase inhibitors. Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure lowering agents with prolonged duration of action
33. Carbonic anhydrase inhibitors. Water soluble 4-sulfamoylphenyl-thioureas as topical intraocular pressure lowering agents with long lasting effects
34. Carbonic anhydrase inhibitors: Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tall more important than the ring?
35. Carbonic anhydrase inhibitors: Synthesis of water-soluble, amino acyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route
36. Carbonic anhydrase inhibitors: Synthesis of water-soluble, topically effective intraocular pressure lowering aromatic/heterocyclie sulfonamides containing 8-quinolinesulfonyl moieties: Is the tail more important than the ring?
37. Carbonic anhydrase inhibitors: Topical sulfonamide antiglaucoma agents incorporating secondary amine moieties
38. Carbonic anhydrase inhibitors: Sulfonamides as anticancer agents?
39. Carbonic anhydrase inhibitors. Sulfonamides incorporating furan-, thiophene- and pyrrole-carboxamido groups possess strong topical intraocular pressure lowering properties as aqueous suspensions
40. Carbonic anhydrase inhibitors. Part 52. Metal complexes ofheteroeyclic sulfonamides: A new class of strong topical intraocular pressure-lowering agents with potential use as antiglaucoma drugs
41. Carbonic anhydrase inhibitors. Part 57. Quantum chemical QSAR of a group of 1,3,4-thiadiazole and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties
42. Carbonic anhydrase inhibitors. Part 61. Quantum Chemical QSAR of a group of benzenedisulfonamides
43. Die Entwicklung neuer Antiepileptika. V. Mitteilung: Pharmakologische Wirkungen einiger Sulfanilamidderivate
44. 2-1,3,4-thiadiazoline
45. Topically active carbonic anhydrase inhibitors. 1. O-Aw1 derivatives of hydroxybenzothiazole-2-sulfonamide
46. Structure - Function relations in human carbonic anhydrase II as studied by site-directed mutagenesis
47. Fine tuning of the catalytic properties of carbonic anhydrase. Studies of a Thr200-His variant of human isoenzyme II
48. Carbon-13 nuclear magnetic resonance probe of active site ionization of human carbonic anhydrase B
49. The catalytic mechanism of carbonic anhydrase
50. The catalytic mechanism of carbonic anhydrase. Hydrogen-isotope effects on the kinetic parameters of the human C isoenzyme
51. Chemical properties of carbonic anhydrase IV, the membrane-bound enzyme
52. The catalytic versatility of erythrocyte carbonic anhydrase. III. Kinetic studies of the enzyme-catalyzed hydrolysis ofp-nitrophenyl acetate
53. Catalysis and inhibition of human carbonic anhydrase IV
54. Inhibitory effect of zonisamide on human carbonic anhydrase in vitro
55. Refined structure of the acetazolamide complex of human carbonic anhydrase II at 1.9 Å
56. X-ray crystallographic studies of the carbonic anhydrase isozymes
57. Carbonic anhydrase inhibitors. Interaction of boron derivatives with isozymes I and II: A new binding site for hydrophobic inhibitors at the entrance of the active site evidenced by docking studies
58. Carbonic anhydrase activators: X-ray crystallographic and spectroscopic investigations for the interaction of isozymes I and II with histamine
59. Topiramate as an inhibitor of carbonic anhydrase isoenzymes
60. Complexes with biologically active ligands, Part 8. Synthesis and carbonic anhydrase inhibitory activity of 5-benzoylamido- and 5-(3-nitrobenzoylamdo)-1,3,4-thiadiazole-2-sulfonamide and their metal complexes
61. Carbonic anhydrase inhibitors. Synthesis of topically effective intraocular pressure lowering agents derived from 5-(ο-aminoalkylcarboxamido)-1,3,4-thiadiazole-2-sulfonamide
62. Carbonic anhydrase inhibitors. Arylsulfonylureido and arylureido-substituted aromatic and heterocyclic sulfonamides: Towards selective inhibitors of carbonic anhydrase isozyme I
63. Carbonic anhydrase inhibitors. Part 34. Synthesis and biological activity of coordination compounds of 5-pivaloylamido-1,3,4-thiadiazole-2-sulfonamide with divalent metal ions
64. Carbonic anhydrase inhibitors: Synthesis and inhibition against isozymes I, II and IV of topically acting antiglaucoma sulfonamides incorporating cis-5-norbornene-endo3-carboxy-2-carboxamido moieties
65. Effects of acetazolamide on cerebral blood flow and brain tissue oxygenation
66. Acetazolamide-induced increase in blood flow to rabbit organs is confirmed using colored microspheres
67. The dose-response relationship of acetazolamide on the cerebral blood flow in normal subjects
68. Noninvasive magnetic resonance imaging evaluation of cerebral blood flow with acetazolamide challenge in patients with cerebrovascular stenosis
69. 123I-IMP single photon emission computed tomography in patients with major cerebral artery occlusive disease: Correlation with positron emission tomography parameters
70. 99mTc-ECD consecutive SPECT method
71. Antiepileptic drug development program
72. Anticonvulsant activity of pyrid-3-yl sulfonyl urea and thiourea
73. Design, synthesis, and anticonvulsant activity of 1-(pyrid-3-ylsulfonamido)-2-nitroethylenes